This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Diekema, D. J.
Right arrow Articles by Pfaller, M. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Diekema, D. J.
Right arrow Articles by Pfaller, M. A

 Previous Article  |  Next Article 

Journal of Clinical Microbiology, January 2005, p. 476-478, Vol. 43, No. 1
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.1.476-478.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Activities of Available and Investigational Antifungal Agents against Rhodotorula Species

D. J. Diekema,1,2* B. Petroelje,1 S. A. Messer,2 R. J. Hollis,2 and M. A Pfaller2,3

Departments of Internal Medicine,1 Pathology, Roy J. and Lucille A. Carver College of Medicine,2 Department of Epidemiology, College of Public Health, University of Iowa, Iowa City, Iowa3

Received 6 July 2004/ Returned for modification 28 August 2004/ Accepted 13 September 2004

Rhodotorula species are emerging pathogens in immunocompromised patients. We report the in vitro activities of eight antifungals against 64 Rhodotorula isolates collected in surveillance programs between 1987 and 2003. Rhodotorula strains are resistant in vitro to fluconazole (MIC at which 50% of the isolates tested are inhibited [MIC50], >128 µg/ml) and caspofungin (MIC50, >8 µg/ml). Amphotericin B (MIC50,1 µg/ml) and flucytosine (MIC50, 0.12 µg/ml) are both active in vitro, and the new and investigational triazoles all have some in vitro activity, with ravuconazole being the most active (MIC50, 0.25 µg/ml).

* Corresponding author. Mailing address: Medical Microbiology Division, C606 GH, Department of Pathology, University of Iowa College of Medicine, Iowa City, IA 52242. Phone: (319) 356-8615. Fax: (319) 356-4916. E-mail: daniel-diekema{at}uiowa.edu.

Journal of Clinical Microbiology, January 2005, p. 476-478, Vol. 43, No. 1
0095-1137/05/$08.00+0     doi:10.1128/JCM.43.1.476-478.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Thompson, G. R. III, Wiederhold, N. P., Sutton, D. A., Fothergill, A., Patterson, T. F. (2009). In vitro activity of isavuconazole against Trichosporon, Rhodotorula, Geotrichum, Saccharomyces and Pichia species. J Antimicrob Chemother 64: 79-83 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Bijie, H., Dzierzanowska, D., Klimko, N. N., Letscher-Bru, V., Lisalova, M., Muehlethaler, K., Rennison, C., Zaidi, M., the Global Antifungal Surveillance Group, (2009). Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: 10.5-Year Analysis of Susceptibilities of Noncandidal Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing. J. Clin. Microbiol. 47: 117-123 [Abstract] [Full Text]  
  • Serena, C., Rodriguez, M. M., Marine, M., Pastor, F. J., Guarro, J. (2007). Combined Therapies in a Murine Model of Blastoschizomycosis. Antimicrob. Agents Chemother. 51: 2608-2610 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Gibbs, D. L., Newell, V. A., Meis, J. F., Gould, I. M., Fu, W., Colombo, A. L., Rodriguez-Noriega, E., and the Global Antifungal Surveillance Group, (2007). Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2005: an 8.5-Year Analysis of Susceptibilities of Candida Species and Other Yeast Species to Fluconazole and Voriconazole Determined by CLSI Standardized Disk Diffusion Testing. J. Clin. Microbiol. 45: 1735-1745 [Abstract] [Full Text]  
  • Pfaller, M. A., Diekema, D. J., Rinaldi, M. G., Barnes, R., Hu, B., Veselov, A. V., Tiraboschi, N., Nagy, E., Gibbs, D. L., the Global Antifungal Surveillance Group, (2005). Results from the ARTEMIS DISK Global Antifungal Surveillance Study: a 6.5-Year Analysis of Susceptibilities of Candida and Other Yeast Species to Fluconazole and Voriconazole by Standardized Disk Diffusion Testing. J. Clin. Microbiol. 43: 5848-5859 [Abstract] [Full Text]  
  • Serena, C., Marine, M., Pastor, F. J., Nolard, N., Guarro, J. (2005). In vitro interaction of micafungin with conventional and new antifungals against clinical isolates of Trichosporon, Sporobolomyces and Rhodotorula. J Antimicrob Chemother 55: 1020-1023 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»